Regulatory T cells (Tregs) are immune cells that play important roles in suppressing autoimmune responses in humans. While the main driver of their suppressive identity is known, an in-depth understanding of the factors that regulate Treg activity throughout their development and maturation is still lacking. To shed some light on the situation, Dr. Ariella Glasner is using mice to identify how different versions of genes—known as alleles—affect Treg activity in various states. Overall, she hopes to gain a better understanding of the genetic and molecular mechanisms of Treg cell differentiation and function, which may pave the way for the development of novel therapeutic approaches against cancer.
Memorial Sloan Kettering Cancer Center | All Cancers | 2018 | Alexander Y. Rudensky, Ph.D.
*Immunotherapy results may vary from patient to patient.
Cancer Research Institute | National Headquarters
29 Broadway, Floor 4 | New York, NY 10006-3111
New research, new treatments, and how we’re working toward a future immune to cervical cancer
Ugur Sahin and Ozlem Tureci, two of this year’s CRI Coley Award recipients, are pioneers of the mRNA vaccines helping us confront COVID-19 and cancer.